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Purpose: To evaluated prognostic factors and impact of the quality of planning of high dose rate brachytherapy 
(HDR-BT) for patients with local or locally advanced prostate cancer treated with external beam radiotherapy 
(EBRT) and HDR-BT. 
Methods and Materials: Between 1997 and 2005, 209 patients with biopsy proven prostate adenocarcinoma were 
treated with localized EBRT and HDR-BT at the Department of Radiation-Oncology, Hospital A. C. Camargo, Sao 
Paulo, Brazil. Patient’s age, Gleason score (GS), clinical stage (CS), initial PSA (iPSA), risk group for biochemical 
failure (GR), doses of EBRT and HDR-BT, use of three-dimensional planning for HDR-BT (3DHDR) and the 
Biological Effective Dose (BED) were evaluated as prognostic factors for biochemical control (bC).  
Results: Median age and median follow-up time were 68 and 5.3 years, respectively. Median EBRT and HDR-BT 
doses were 45 Gy and 20 Gy. The crude bC at 3.3 year was 94.2%. For the Low, intermediate and high risk 
patients the bC rates at 3.3 years were 91.5%, 90.2% and 88.5%, respectively. Overall survival (OS) and disease 
specific survival rates at 3.3 years were 97.8% and 98.4%, respectively. On univariate analysis the prognostic 
factors related bC were GR (p= 0.040), GS < 6 (p= 0.002), total dose of HDR-BT > 20 Gy (p< 0.001), 3DHDR (p< 
0.001), BED-HDR > 99 Gy1.5 (p<0.001) and BED-TT > 185 (p<0.001). On multivariate analysis the statistical 
significant predictive factors related to bC were RG (p< 0.001), HDR-BT > 20 Gy (p=0.008) and 3DHDR (p<0.001).   
Conclusions: we observed that the bC rates correlates with the generally accepted risk factors described in the 
literature. Dose escalation, evaluated through the BED, and the quality of planning of HDR-BT are also important 
predictive factors when treating prostate cancer. 
Key words: high-dose rate brachytherapy, external beam radiotherapy, prostate cancer, RTOG-ASTRO Phoenix, biochemical 
failure, biochemical control 
Introduction 
World population median age is increasing as 
result of improvement in health care. With the 
emergence of prostatic specific antigen (PSA) 
screening, the proportion of cases of prostate cancer 
(PCa) diagnosed has been increasing. PCa is one of the 
most prevalent malignancies affecting men in the 
developed world. For male population of western 
countries, the probability of dyeing of PCa is about 3% 
[1]. The best management of both localized and locally 
advanced PCa remains controversial with a consensus 
that surgery, radiotherapy, hormonal therapy, and 
active surveillance can be used isolated or in 
combination to treat the different of risk groups (RG) 
for biochemical failure (BF) [2].  
Significant clinical data are available 
demonstrating that patients treated with radiation 
therapy have a significantly better outcome as the dose 
to the prostate is increased [3-5]. There are also many 
published results demonstrating that conformal high 
dose rate brachytherapy (HDR-BT) is a successful 
method for delivering higher dose of radiation to the 
prostate [6,7]. HDR-BT is a very precise and conformal 
way of dose delivering comparable to 
three-dimensional conformal (3DRT) and intensity 
modulated (IMRT) external beam radiotherapy (EBRT) 
[8]. HDR-BT also has some potential additional 
advantages over normal tissues sparing and on 
reducing miss dose to the prostate, due imprecise 
target localization, treatment setup uncertainties, Int. J. Med. Sci. 2008, 5 
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organ motion and or deformation during the 
treatments, with a relative low incidence of severe 
acute and late side effects [9-11]. In this study we 
evaluated the relationship between quality of planning 
and prognostic factors related to biochemical control 
(bC), according to the RTOG-ASTRO Phoenix 
Consensus Conference [12] and the quality of planning 
of HDR-BT. 
Material and methods 
This is a retrospective analysis performed to 
assess the efficacy of the use of three-dimensional 
(3DHDR) over bi-dimensional planning (2DHDR) of 
HDR-BT and EBRT in a population of patients with 
clinically localized or locally advanced PCa. This work 
on human beings complies with the principles laid 
down in the DECLARATION OF HELSINKI and has 
been approved by the ethical committee of Hospital A. 
C. Camargo, Sao Paulo, Brazil. 
Patient Group 
The charts of patients with local or locally 
advanced biopsy proven prostate adenocarcinoma 
treated at the Department of Radiation Oncology, 
Hospital A.C. Camargo, Sao Paulo, Brazil were 
retrospectively reviewed. Details as Gleason scored 
(GS), the initial PSA value, clinical stage (CS) using the 
1992 AJCC clinical stage and use of 3D HDR-BT 
planning were collected.  
Definition of risk group for biochemical failure 
Patients were grouped into 3 different subgroups 
of risk for BF. The low risk (LR) group encompassed 
patients with CS T2a or lesser, GS less than 7 and initial 
PSA value equal or lesser than 10 ng/ml. Patients with 
either stage T2b, GS 7 or initial PSA value ranging 
from 10–20 ng/ml were considered intermediate risk 
(IR) for BF. The remaining patients or patients who 
presented two or more of the characteristics of the IR 
group were grouped into the high risk (HR) group for 
BF. At the discretion of the referral urologists, patients 
into any of the groups received a course of 
neoadjuvant androgen blockage (NAAD), with 
goserelin and or flutamide or ciproteron acetate, 3 to 6 
months prior to EBRT. Patients 
External beam radiotherapy (EBRT) 
In the first three years of treatment conventional 
EBRT planning was used. In summary, patients had a 
pretreatment diagnostic computed tomography scan 
(CT), urethrogram and rectal contrast to assist in 
defining prostate, seminal vesicles and normal tissue 
volumes at risk. The prostate and seminal vesicles 
were irradiated through a 6 MV Varian linear 
accelerator, with four-field box technique and 
individual protections with cerrobend blocks. After 
1999, all patients were treated with localized 3DRT. 
High dose rate brachytherapy (HDR-BT) 
The technique of HDR-BT has been previously 
published elsewhere [8]. The volume limitation for this 
approach is prostate volume less than 60 cc. In brief, 
the implant procedures were performed 10 to 15 days 
after the end of EBRT, with no prior pre-planning. At 
the beginning of the implant, a Foley catheter was 
inserted to help visualize the urethra. With the patient 
in lithotomic position and under spinal anesthesia, a 
TRUS probe from Siemens Sonoline Prima Ultrasound 
System (Siemens Medical Solutions–Ultrasound 
Division, Mountain View, CA) was positioned as 
parallel as possible to the prostatic urethra. At the first 
moment two metallic markers were inserted into the 
gland, one in the apex and the other in the base of the 
prostate, to ascertain quality control of any needle 
displacement during the treatment and to allow 
corrections whenever it was necessary. All the 
implants were performed with steel needles with 75% 
of the needles located on the periphery and 25% 
around the urethra. The tips of the needles were 
always kept below the bladder mucosa and out of the 
urethra. In the 2DHDR technique the apex and base of 
the gland were identified using transverse and sagittal 
TRUS images, which were also used for defining the 
active length of each needle inside the prostate. After 
the end of the implant a CT scan was performed to 
ensure that the entire gland volume was implanted, 
but semi-orthogonal X rays were used for planning 
and dosimetric calculations. Plans were generated 
with the Nucletron Planning System BPS V11.2 
(Nucletron B.V., Veenendaal, The Netherlands). In 
reconstruction needles were digitized at both ends and 
at least three axial plans with 10-mm increment were 
generated. The dose prescription was in a point of 
minimum dose defined in the central plan of the 
implant. The treatment was optimized using the 
standard geometric optimization and median isodose 
line prescription was 85% (range 82–91%). Dose 
prescriptions were 4 or 5 Gy per fraction, b.i.d., up to 
16 Gy for LR and 20 Gy for IR and HR patients. 
Treatment was delivered via the micro-Selectron-HDR 
Ir-192 remote afterloading system, source strength 
ranging from 1.84 to 4.61 cGy h-1 m-2 (4.5–10 Ci). 
On August, 2000, we switched to 3D image 
guided CT based planning brachytherapy. The 
Siemens Sonoline Prima Ultrasound System (Siemens 
Medical Solutions–Ultrasound Division, Mountain 
View, CA) and a Winston-Barzell track-stepper unit 
(Barzell-Whitmore Maroon Bells, Sarasota, FL) with 
integrated needle guide were used for the implant 
procedure. After the end of insertion of the needles the Int. J. Med. Sci. 2008, 5 
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TRUS probe was removed, legs were laid flat, and 
plain orthogonal pelvic radiographs were taken with 
needles in place to identify the metallic markers and 
ensure quality control.  
The patients were moved directly after the 
implantations to a CT simulator were a planning pelvic 
CT was done. Three-millimeter-step and 
three-millimeter-thick CT slices were collected using a 
spiral CT and sent on-line via network to the 
BrachyVision Planning System (Varian Medical 
Systems, Palo Alto, CA). The clinical target volume 
(CTV) and critical organs including bladder, rectum, 
and urethra were then contoured. The following 
volumes were defined: the CTV - Clinical Target 
Volume - represented by the entire prostate, the 
Planning Target Volume- PTV- represented by an 
expansion of the CTV 3 mm in the lateral and anterior 
dimension for each CT axial image. The most cephalad 
and caudad axial plane containing the prostate were 
expanded 5 mm. No expansions were made for the 
posterior region, given a PTV approximately 6 mm 
larger in the lateral, 3mm in the anterior and 10 mm 
longer in the caudal-cephalic dimensions than the 
CTV. Implant catheters were digitized using the CT 
reconstruction and only dwell positions inside the PTV 
were activated. The outer most mucosa surface of 
bladder and rectum were contoured in all CT images. 
The urethra was defined by the outer surface of the 
Foley catheter. Only the urethral volume within the 
PTV was contoured. The 3DHDR dose optimization 
was based on inverse planning, with at least 95% of the 
PTV volume receiving 100% of prescribed dose (V100 
> 95% of prescribed dose) [13]. Dose prescriptions 
ranged from 4 to 6 Gy per fraction, b.i.d., up to 16 Gy 
for LR and 20 or 24 Gy for IR and HR patients, 
respectively. 
After completion of treatment patients were seen 
in follow-up 1 month later and after that every 2-4 
months for the first 24 months. Thereafter patients 
were seen in follow up every 6-12 months.  
Calculation of Biologically Effective Doses (BED)  
To facilitate comparison between different 
fractionation schedules discussed the biologically 
effective doses (BED) for PCa were calculated and the 
iso-effect model using the LQ was used. The α/β-value 
assumed for the PCa was of 1.5 Gy, which is supported 
by radiobiological analyses [14]. Two assumptions 
were made: 1) complete repair occurs between 
fractions, and 2) there is no time factor.  
Statistical analysis 
The bC were calculated as the interval from 
pathologic diagnosis of PCa to BF or dead due prostate 
cancer progression. Date of BF, a rise in 2 ng/ml after 
the nadir had been richen, was defined according to 
the RTOG-ASTRO Phoenix Consensus Conference 
[12]. Pearson chi-square and t tests were used to 
compare differences in categorical and continuous 
patient characteristics, respectively. For disease 
specific survival (DSS) calculations only patients who 
died due prostate cancer were censored. Survival data 
were generated using the Kaplan-Meier method, with 
log-rank test used to compare equality of survivor 
functions. The Cox proportional hazard model was 
used for multivariate analysis. The covariates in 
multivariate analysis were BED from EBRT and 
HDR-BT, use of tridimensional planning for HDR-BT 
and risk group for BF. These variables were entered 
into the analysis using a stepwise procedure. Once the 
best model was selected, group risk was entered into 
the logistic regression last, to isolate its impact as much 
as possible. Statistical tests were performed using SPSS 
13.0 (SPSS, Chicago, IL). 
Results  
There were 234 patients treated with combination 
of EBRT and HDR-BT between 1997 and 2005 at the 
Department of Radiation Oncology, Hospital AC 
Camargo, Sao Paulo, Brazil. Fifteen patients were 
excluded from the analysis because of they were lost to 
follow up after treatment. Seven patients had whole 
pelvis EBRT and were also excluded from the analysis. 
Three patients did not reach a nadir value bellow 1.0 
ng/ml after the end of treatment and a revision of their 
charts showed that they already had metastatic disease 
at the time of initial approach, being also excluded 
from this analysis. Median age of the remaining 209 
patients was 68 years (range, 47-83 years). Median 
follow-up was 5.3 years (range, 2 –10). There were 75 
(35.8%) of patients into LR, 66 (31.6%) into IR group 
and 68 (32.6%) into HR group. Characteristics of 
patients are shown in Table 1. 
T h e  d o s e  o f  E B R T  r a n g e d  f r o m  3 6  t o  5 4  G y  
(median 45 Gy) given in 20 to 30 daily fractions of 1.8 
or 2.0 Gy. The total EBRT treatment time ranged from 4 
to 7 weeks (median 5 weeks). The HDR-BT was 
performed after one to two weeks of the completion of 
EBRT in 204 patients. Five patients started their 
treatment by HDR-BT and after that had a course of 
EBRT. The total treatment time ranged from 5 to 9 
weeks (median 7 weeks). The dose of HDR-BT ranged 
from 16 to 24 Gy given in 4 fractions, BID in two days. 
Median HDR-BT dose was 20 Gy.  
The BED was calculated assuming an α/β ratio of 
1.5 for PCa. The median BED for EBRT (BED-RT) was 
104 Gy1.5 (range 84-118.8 Gy1.5) and for HDR-BT 
(BED-HDR) was 76 Gy1.5 (range 58.7-120 Gy1.5). The 
total BED (BED-TT) ranged from 142.7 Gy1.5 to 236.7 Int. J. Med. Sci. 2008, 5 
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Gy1.5 with a median of 185 Gy1.5 (s.d. 18.5). 
Table 1- Patients characteristics 
 
 
Overall survival (OS) rates at 3.3, 5 and 10 years 
were 97.8%m 95.7% and 90.6% respectively. The 3.3-, 
5- and 10-year actuarial DSS rates were 98.4%, 97.7% 
and 95.5%, respectively, as shown in Figure 1. Eleven 
patients were dead at the time of this analysis. Five 
(2.4%) patients died due prostate cancer disease 
progression (local or distant) and 6 (2.9%) of other 
causes (3 of cardiologic related disease, 2 of a new 
second primary tumor and 1 of surgical complication 
after a salvage prostatectomy).   
The crude bC rate at 3.3 year was 94.2%. For the 
LR, IR and HR the bC rates at 3.3 years were 91.5%, 
90.2% and 88.5%, respectively, as shown in figure 2.  
 
 
Figure 1 – Disease specific survival. 
 
Figure 2 – Biochemical control plots according to the risk group 
for BF. 
 
On univariate analysis the prognostic factors 
related bC were GR (p= 0.040), GS < 6 (p= 0.002) and 
total dose of HDR-BT > 20 Gy (p< 0.001). (Table 2)   
Table 2- Univariate analysis 




Regarding the BED, we observed that the 
BED-HDR > 99 Gy1.5 and BED-TT (p<0.001) were 
statically significant perceptive factors related to bC 
instead of the BED-RT (p= 0.215) as shown in Table 3.  
When evaluating the quality of planning we 
observed a survival advantage with 3DHDR (p< 
0.001). (Figure 3). 
On multivariate analysis the statistical significant 
predictive factors related to bC were RG p< 0.001 (CI – 
1.147-3.561), HDR-BT > 20 Gy p=0.008 (CI – 
1.127-2.258) and 3DHDR p<0.001 (CI- 1.369-2.2696).  
At the discretion of the referral urologists, 
patients into any of the groups received a course of 
NAAD. The population was well balanced in all 
groups with a minimum expected of 28 patients per 
subgroup. A hundred and six (50.7%) patients had no 
NAAD. When exploring the influence of NAAD for 
the different RG on bC, we observed no statically 
significant benefit of its in any group (p= 0.604). (Table 
4). 
 









Figure 3 – Bichemical control plots acording to risk group for 





Figure 4 – Hazard functions according to the risk group for BF. 
   
Discussion 
The main advantage of HDR-BT is its ability to 
deliver a relative high dose of radiation within a Int. J. Med. Sci. 2008, 5 
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well-defined volume, with a rapid fall-off of dose 
outside the implanted area. This approach is ideal for 
the treatment of prostate cancer, where the gland lays 
very close to critical normal tissues, in particular the 
anterior rectal wall and bladder neck. Several 
retrospective studies with more than 5-year follow up 
have previously described the outcome of patients 
treated with combination of EBRT and HDR-BT [7, 
15,16), but data from prospective randomized trail 
comparing results of this combination with dose 
escalation RT3D or IMRT is still missing.  
To our knowledge, this is the first paper that 
explores the ability of 3DHDR on impacting in the final 
results. The use of 3DHDR was significantly related to 
the bC rates, in both uni and multivariate analysis (p< 
0.001). Based in the use of 3D planning Martin et al. 
described this same strategy to enable real time 
distribution of the isodose in all CT slices, observing an 
increase accuracy of the delivery of the prescribed 
dose.  
There is clinical evidence that suggests that 
prostate tumors contain a low proportion of 
proliferating cells, having a lower α/β ratio than the 
other epithelial tumors, in the range of 1.2–2.5 [17, 18]. 
We assumed, for BED calculation purposes a α/β ratio 
of 1.5 Gy for tumor and no correction for tumor 
repopulation in the interval between fractions was 
performed. The BED was calculated assuming a α/β 
ratio of 1.5 for PCa. The median BED for EBRT 
(BED-RT) was 104 Gy1.5 (range 84-118.8 Gy1.5) and for 
HDR-BT (BED-HDR) was 76 Gy1.5 (range 58.7-120 
Gy1.5). The total BED (BED-TT) ranged from 142.7 Gy1.5 
to 236.7 Gy1.5 with a median of 180 Gy1.5 (s.d. 18.5). 
The total BED (BED-TT) ranged from 142.7 Gy1.5 
to 236.7 Gy1.5. We observed a trend toward to a better 
bC rate for all risk groups when a BED-TT higher than 
185 Gy1.5 was administered (p< 0.001). Similarly, a 
study by Tang et al. [19] evaluated results of 88 
patients treated with EBRT alone (66 Gy) and EBRT (46 
Gy) combined to HDR-BT (16 Gy to 20 Gy), the same 
dose levels e observed in this study, but with no 
NAAD was allowed in that group of patients. For the 
HDR-BT cohort, the overall actuarial 5-year bC was 
67.4%. They noted a significant advantage (p= 0.011) 
when BED calculations were used to compare results 
of HDR-BT associated to EBRT. They have also 
compared the results in terms of HDR-BT total dose, 16 
Gy versus 20 Gy, observing that the 5-year bC rates, 
using the RTOG-ASTRO Phoenix definition, were 
58.8% and 77.3%, respectively (p= 0.07). In our analysis 
the bC rates had a statistical significant difference 
when total HDR-BT doses administered were < 20 Gy 
(79.8%) and > 20Gy (86.3%), p< 0.001. We can also 
observe that the dose level of 66 Gy given in 33 
fractions has a considerable inferior BED value than 
the same nominal total dose given by 46 Gy in 23 
fractions and 20 Gy given in 4 fractions of HDR-BT. 
Our results in terms of dose levels of HDR-BT for the 
different RG have shown an improvement in bC with 
HDR dose escalation, with a trend toward better bC 
rates when BED-TT dose over 180 Gy1.5 was 
administered (p< 0.001).   
Galalae et al [20] also investigated the long-term 
outcome by GR using HDR-BT and EBRT with or 
without NAAD. There were 611 patients grouped as 
follows: 46 patients into LR, 188 patients into IR and 
359 patients considered HR. Using the ASTRO 
definition for BF they observed that the actuarial bC 
and disease free survival rates at 5-year and 10-year 
were 77%, 67%, 73% and 49%, respectively. For the 
different RG the actuarial 5-year bC rates were 96% for 
LR, 88% for IR and 69% for HR. They observed that GS 
and GR were statistical significant predictive factors of 
bC, what we also confirmed in the present study, were 
GS (p= 0.002) and RG (p= 0,040) were statistical 
significant predictive factors for BF. They observed 
that CS and iPSA were also statistical significant 
predictive factors, what was not confirmed in this 
study.  
Deger et al. [21] evaluated 422 patients with 
localized prostate cancer treated between 1992 and 
2001 with HDR-BT and 3DRT. All patients underwent 
laparoscopic pelvic lymph node dissection to exclude 
patients with lymphatic involvement. The BF was also 
defined according to the ASTRO criteria. The bC 
according to RG were 100% T1, 75% for T2 and 60% T3 
at 5 years. Five-year bC were 81% in the LR, 65% in the 
IR and 59% in the HR. Five-year OS and bC were 87% 
and 94%, respectively. They also observed that iPSA, 
RG and age were significantly related to bC. In our 
study the use of NAAD was not associated with better 
bC (p= 0.425). When the patients were grouped 
according to the of BF and use of NAAD, there was not 
a statistical significance for a better bC related to the its 
use (p=0.604).   
There are a scarce number of papers that have 
published the results of HDR-BT and EBRT for PCa 
using the RTOG-ASTRO Phoenix definition. This 
definition states that “To avoid the artifacts resulting 
from short follow-up, the reported date of control 
should be listed as 2 years short of the median 
follow-up” [12]. Chin et al. [22] published the results of 
65 consecutive patients treated between 1998 and 2004 
with combination of EBRT and HDR-BT given in 2 
fractions. Sixty patients (92.3%) were considered IR or 
HR. With a median follow-up of 3.5 years (range 
0.6-5.8), two patients had died of metastatic disease 
and other four patients had BF, giving a 3-year Int. J. Med. Sci. 2008, 5 
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actuarial bC rate of 90.8%. Yamada et al. [23] also 
reported the results of 105 patients consecutively 
treated between 1998 and 2004 with EBRT (45-50.4 Gy) 
and HDR-BT (5.5-7.0 Gy per fraction). With a median 
follow-up of 44 months (8-79 months), the actuarial 
5-year bC rates for LR, IR and HR were 100%, 98%, and 
92%, respectively. In the current study the actuarial bC 
rates at 5-year were 91.8% for LR group, 79.3% for IR 
group and 69.1% for HR group (p= 0.040), respectively. 
Patients considered HR have more chances of BF. 
This phenomenon could be a consequence of current 
inadequate imaging of lymph node or bone metastasis 
or due subclinical metastatic spread that remains 
undetectable during radical treatment. However, 
tumor biology itself could lead to the progression of 
the disease in the HR group. As a consequence, 
risk-adapted therapy is very important in these cases. 
The combination of EBRT and HDR-BT is an 
alternative strategy of dose escalation that can 
potentially achieve an even higher BED given to the 
t u m o u r  w h e n  c o m p a r e d  3 D R T  o r  I M R T ,  b u t  f o r  
patients at HR the localized dose given by HDR-BT 
may be a potential disadvantage, because a 
microscopic spread outside the prostate and even its 
capsule may exist. In these cases, the combination of 
HDR-BT and EBRT can provide treatment to potential 
areas of microscopic spread. What is still not answered 
is if adding pelvic radiation, instead to localized EBRT 
in combination to HDR-BT for PCa patients with a 
more than 15% risk of positive lymph nodes will really 
improve outcome, and is stil controversial in literature 
[24].  
A hundred and six (50.7%) patients had no 
NAAD in our analysis. Despite being a retrospective 
analysis, the patients were well balanced when having 
or not NAAD into the RG as seem in table 2. The use of 
NAAD is also still controversial for patients with IR to 
HR. Martinez et al. [25] in a study of 1,260 patients 
treated with pelvic EBRT and HDR-BT observed 
similar OS, DFS and bC for patients who were treated 
with or without the addition of a course of NAAD up 
to 6 months prior to radiation. They observed that 
NAAD did not confer a therapeutic advantage, and 
instead of that added side effects and cost. 
Furthermore, for the most unfavourable group, there 
was a higher rate of distant metastasis and more 
prostate cancer-related deaths. We could not observe a 
statistical significant benefit on BC rates with the use of 
NAAD in none of the GR. 
Vargas et al. [26] performed a matched-pair 
analysis of patients treated with combined EBRT and 
HDR-BT from January 1993 to March 2003. A total of 
1432 were evaluated. There were 755 cases identified 
as having a risk of pelvic limphonodes positive of 
more than 15% using the Roach formula. Of these, 255 
cases were treated without pelvic EBRT and randomly 
matched by GS, CS and iPSA to 500 cases treated with 
pelvic EBRT, resulting in 250 pairs. As results they 
observed that BF, and OS were not significantly 
different for patients treated with pelvic radiotherapy. 
At a median follow-up of 4 years the bC and OS rates 
were 78%, 86%, 89% and 88%, respectively. In our 
analysis, the actuarial 5- and 10-year OS were 95.7% 
and 90.6%, while the actuarial bC rates at 5- and 
10-year for the different RG were 91.8% and 82.3% for 
LR, 79.3% and 67.7% for IR, and 68.5% and 41.3% for 
HR (p= 0.040), respectively.   
Our results and others suggested that bC is 
related not just clinical characteristics of patients, as 
RG and GS, but it is also related to treatment 
parameters as total dose of HDR-BT and BED. To our 
knowledge, this is the first paper that found a positive 
relationship between the quality of planning and the 
outcome.  
So far in our own experience, HDR-BT associated 
to EBRT is a successful form of treatment of PCa, with 
results comparable to published data, results that tend 
to be even better with the introduction of image 
guided brachytherapy.  
In conclusion, dose escalation, evaluated through 
BED, and 3DHDR are predictive factors for bC, as well 
as other already accepted factors described in 
literature as GS and RG. The challenges for the future 
are to determine which treatment option will have the 
best result for each patient and the role of NAAD when 
using EBRT combined to HDR-BT for IR and HR 
patients.  
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